Discontinuation due to immune‐related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non‐small cell lung cancer

BACKGROUND: Immune‐related adverse events (irAEs) should be anticipated with treatment by immune checkpoint inhibitors (ICIs). Although the relationship between irAEs and efficacy of ICI has been reported, it has not yet been clarified whether the benefit from ICI outweighs the low frequency of proc...

Descripción completa

Detalles Bibliográficos
Autores principales: Komiya, Kazutoshi, Nakamura, Tomomi, Abe, Tomonori, Ogusu, Shinsuke, Nakashima, Chiho, Takahashi, Koichiro, Kimura, Shinya, Sueoka‐Aragane, Naoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718019/
https://www.ncbi.nlm.nih.gov/pubmed/31328416
http://dx.doi.org/10.1111/1759-7714.13149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718019/
https://www.ncbi.nlm.nih.gov/pubmed/31328416
http://dx.doi.org/10.1111/1759-7714.13149

Ejemplares similares